Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) President Sells 9,000 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON) President Joshua Isner sold 9,000 shares of Axon Enterprise stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $683.31, for a total transaction of $6,149,790.00. Following the sale, the president now owns 308,714 shares in the company, valued at $210,947,363.34. This represents a 2.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $728.39 on Friday. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $732.22. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $56.71 billion, a price-to-earnings ratio of 188.21, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The business has a 50 day simple moving average of $580.48 and a 200-day simple moving average of $591.44.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same quarter in the previous year, the firm earned $1.15 earnings per share. The firm’s revenue for the quarter was up 31.3% compared to the same quarter last year. As a group, equities research analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AXON shares. Barclays lifted their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. The Goldman Sachs Group lifted their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research report on Wednesday. Needham & Company LLC lifted their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Finally, Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $652.73.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors have recently modified their holdings of the business. TCTC Holdings LLC grew its holdings in shares of Axon Enterprise by 75.0% during the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 24 shares during the last quarter. Fourth Dimension Wealth LLC bought a new position in shares of Axon Enterprise during the fourth quarter valued at approximately $30,000. Bartlett & CO. Wealth Management LLC grew its stake in Axon Enterprise by 132.0% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock worth $31,000 after buying an additional 33 shares during the last quarter. Catalyst Capital Advisors LLC bought a new position in Axon Enterprise during the 1st quarter worth $32,000. Finally, New Wave Wealth Advisors LLC bought a new position in Axon Enterprise during the 4th quarter worth $40,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.